Compass Therapeutics, Inc. (CMPX)
(Real Time Quote from BATS)
$1.68 USD
+0.02 (1.21%)
Updated Sep 18, 2024 11:32 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CMPX 1.68 +0.02(1.21%)
Will CMPX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CMPX
Compass Therapeutics just upgraded at Ladenburg, here's why
Compass Therapeutics to Participate in Upcoming Investor Events
Compass Therapeutics files $300M mixed securities shelf
Compass Therapeutics files $300M mixed securities shelf
Compass Therapeutics Strategy Pivot and Outperform Rating Amidst Clinical Setbacks